Milner Institute announces strategic collaboration with NC3Rs
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate their in vitro models of human disease into industry-relevant genetic assays. The collaboration involves a funding...
Milner affiliate STORM Therapeutics initiate phase I clinical trials
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3. STORM Therapeutics is a clinical stage biotechnology company creating...
MSD joins Milner Therapeutics Consortium
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the company’s investment in a new Discovery Centre in London, located in the heart of the Knowledge Quarter. MSD scientists in...
Milner pharma partner visit to Barcelona affiliated institutes
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering wider cross-sector collaboration. Colleagues from affiliated academic institutes have participated in our annual...